Abstract
Despite more than a century of evolving federal legislation, there remain many unapproved drugs on the United States (US) market. This article reviews the history of drug approval in the US, beginning with the landmark Pure Food and Drug Act of 1906, through to the development of the US Food and Drug Administration (FDA). The Pure Food and Drug Act of 1906 was the first comprehensive federal legislation covering drug regulation. Intervening legislation, such as the Federal Food, Drug, and Cosmetic Act of 1938 and Kefauver-Harris Amendments in 1962, was later instituted. In June 2006, a century after the development of the FDA as an enforcement body, an initiative was undertaken to remove unapproved drugs from the marketplace. The Marketed Unapproved Drugs — Compliance Policy Guide outlines enforcement policies aimed at efficiently and rationally bringing all unapproved and illegally marketed drugs into the approval process, or discontinuing their manufacture, distribution, and sale. The FDA has been actively pursuing control of unapproved drugs in recent years, with an approach concentrating on drug safety to ensure optimal public health and consumer protection.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Reference
US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). Marketed Unapproved Drugs — Compliance Policy Guide. June 2006. Available at: http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/UCM074382. Accessed March 26, 2011.
Fisher CD. Dr. Wiley and the Pure Food Laws. Progress. 1909;8:91–94.
Barkan ID. Industry invites regulation: the passage of the Pure Food and Drug Act of 1906. Am J Public Health. 1985;75:18–26.
Upton Sinclair. Encyclopedia Britannica. Encyclopedia Britannica Online. Encyclopedia Britannica, 2011. Available at: http://www.britannica.com/EBchecked/topic/545642/Upton-Sinclair. Accessed March 26, 2011.
Chhabrar R, Kremzner ME, Kiliany BJ. FDA policy on unapproved drug products: past, present, and future. Ann Pharmacother. 2005;39:1260–1264.
Ballentine C. Taste of raspberries, taste of death: the 1937 Elixir Sulfanilamide Incident. FDA Consumer Magazine, June 1981. Available at: http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SulfanilamideDisaster/default.htm. Accessed March 26, 2011.
Moghe VV, Kulkarni U, Parmar UI. Thalidomide. Bombay Hosp J. 2008;50:472–476.
von Moos R, Stolz R, Cherny T, Gillessen K. Thalidomide: from tragedy to promise. Swiss Med Wkly. 2003;133:77–87.
Bren L. Frances Oldham Kelsey: FDA Medical Reviewer leaves her mark on history. FDA Consumer Magazine, Mar–Apr 2001. Available at: http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2001/201_kelsey.html. Accessed March 26, 2011.
Botting J. The history of thalidomide. Drug News Perspect. 2002;15:604–611.
Silverman WA. The schizophrenic career of a “monster drug”. Pediatrics. 2002;110:404–406.
Autor DM. The Unapproved Universe. January 9, 2007. Available at: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm118338.pdf. Accessed March 26, 2011.
Karst KR. Marketed unapproved drugs: overview and FDA enforcement policies. August 10, 2006. Available at: http://www.hpm.com/pdf/MARKETED%20UNAPROVED%20DRUGS-%20OVERVIEW.pdf. Accessed March 27, 2011.
Approved Drug Decision Tree. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm119916.pdf. Accessed March 27, 2011.
US Department of Health and Human Services. Food and Drug Administration. Timed-release drug products containing guaifenesin; enforcement action. Federal Register. 2007;72:29517–29519.
US Department of Health and Human Services. Food and Drug Administration. Carbinoxamine products; enforcement action dates. Federal Register. 2006;71:33462–33462.
US Department of Health and Human Services Food and Drug Administration. Press release: FDA orders 2 companies to stop marketing unapproved nitroglycerin tablets. March 16, 2010. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm204744.htm. Accessed March 27, 2011.
US Department of Health and Human Services. Food and Drug Administration. Questions and answers for consumers about FDA’s action involving unapproved nitroglycerin sublingual tablets. March 16, 2010. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm204351.htm. Accessed March 27, 2011.
US Department of Health and Human Services. Food and Drug Administration. Drug products containing colchicine for injection; enforcement action. Federal Register. 2008;75:7565–7567.
Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol. 2000;27:1334–1337.
Speeg KV, Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology. 1992;15:899–903.
Speeg KV, Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by a kidney multidrug transporter studied in vivo. J Pharmacol Exp Ther. 1992;261:50–55.
Cocco G, Chu DCC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. Eur J Intern Med. 2010;21:502–508.
Yang LPH. Oral colchicine (Colcrys) in the treatment and prophylaxis of gout. Drugs. 2010;70:1603–1613.
Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine. 2006;73:672–678.
Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48:1422–1431.
Food and Drug Administration Information for Healthcare Professionals: New Safety Information for Colchicine. 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174315.htm. Accessed July 5, 2011.
US Department of Health and Human Services. Food and Drug Administration. Single-ingredient oral colchicine products; enforcement action dates. Federal Register. 2010;73:60768–60771.
Colcrys® Full Prescribing Information. September 6, 2010. Available at: http://www.colcrys.com/assets/pdf/COLCRYS_Full_Prescribing_Information.pdf. Accessed March 28, 2011.
Kesselheim AD, Solomon DH. Incentives for drug development. The curious case of colchicine. N Engl J Med. 2010;362:2045–2047.
Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-fourhour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–1068.
Jayaprakash V, Ansell G, Galler D. Colchicine overdose: the devil in the detail. NZ Med J. 2007;120:U2402.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Nasr, A., Lauterio, T.J. & Davis, M.W. Unapproved drugs in the united states and the food and drug administration. Adv Therapy 28, 842–856 (2011). https://doi.org/10.1007/s12325-011-0059-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0059-4